The Claim
In mice, a single dose of the monoclonal antibody SRK-015, which inhibits the proteolytic activation of myostatin precursor forms, increases gastrocnemius muscle mass by 17.5% and prevents dexamethasone-induced muscle atrophy without impairing muscle quality.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice, a single injection of the antibody SRK-015 increases muscle mass by 17.5% and stops muscle loss caused by dexamethasone without reducing muscle quality.
See the scientific wording
In mice, a monoclonal antibody (SRK-015) that blocks the proteolytic activation of myostatin precursor forms increases gastrocnemius muscle mass by 17.5% after a single dose and prevents dexamethasone-induced muscle atrophy, with no adverse effects on muscle quality, suggesting that inhibiting extracellular myostatin activation is a viable strategy for combating muscle wasting.
A special antibody binds to inactive myostatin before it can be activated, preventing the release of the active growth factor. Without active myostatin, muscle cells stop breaking down proteins and start building more muscle, leading to larger muscles and protection against muscle loss.
What the research says
1 studyStudy: Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
Scientists gave mice a special antibody that stops a protein called myostatin from becoming active, and the mice grew bigger, stronger muscles without any harm. It also stopped muscle loss caused by a steroid drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.